Monthly Archives: December 2011
Denali Concrete Management Inc. Announces The Commencement Of Patient Enrollment For The Phase 3 Dry Eye Syndrome Study
Denali Concrete Management Inc. (OTCBB: DCMG) announced that it has commenced patient enrollment for a phase 3 clinical study of the safety and efficacy of CF101, daily administered orally, in patients with moderate-to-severe Dry Eye Syndrome. This multi-center clinical trial is conducted in the United States, Europe and Israel...
Happy New Year!
Dear Friends, This is my favorite week of the year. I love that my older two are back from school, we have no hockey scheduled, I take a few days off, etc. It’s a nice break from the routine. I wish you all a very Happy New Year! Stay well. Randy Randall V. Wong, M.D. [...]
Durezol And Durasal, Don’t Get Them Mixed Up, FDA Warns
Eye drug Durezol (difluprednate ophthalmic emulsion) and wart remover Durasal (salicylic acid) may sound similar, but getting them mixed up can happen, and with potentially serious consequences, the Food and Drug Administration has warned doctors, pharmacists and other health care professionals...
Status of Strategic Partnership Discussions Related to RGN-259 Ophthalmic Eye Drop
ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) is updating stockholders on the status of strategic discussions related to its ophthalmic drug candidate, RGN-259. Since data related to its Phase 2 dry eye clinical trial was released in November showing that RGN-259 had statistically significant benefits over placebo in certain signs and symptoms of dry eye syndrome, the company has been directly engaged in licensing.
Scientists Develop Animal Model for TB-Related Blindness
Working with guinea pigs, tuberculosis experts at Johns Hopkins and elsewhere have closely mimicked how active but untreated cases of the underlying lung infection lead to permanent eye damage and blindness in people. Lead study investigator and Johns Hopkins infectious disease specialist Petros Karakousis, MD, says the new animal model should hasten development of a badly needed, early diagnostic test for the condition.
Breakthrough In Treatment To Prevent Blindness
A UCSF study shows a popular treatment for a potentially blinding eye infection is just as effective if given every six months versus annually. This randomized study on trachoma, the leading cause of infection-caused blindness in the world, could potentially treat twice the number of patients using the same amount of medication...
A Girl With Photophobia
What condition do you suspect is present in this 8-year-old girl with photophobia and ptosis in both eyes?
Medscape Ophthalmology
Medscape Ophthalmology
Two-At-Once Visual Field Testing: More Efficient, Equally Accurate
Ophthalmology practices could save time and money by performing visual field (VF) testing on more than one patient at a time, say researchers at the University of Michigan. Their study, published online November 23 in Ophthalmology, found no decrease in VF testing performance or reliability when two patients are tested simultaneously in the same room, by one technician.
Benchmarking Cataract Surgery
Is it even possible to develop valid indicators for quality outcomes in cataract surgery?
Medscape Ophthalmology
Medscape Ophthalmology
ORNL Image Analysis Prowess Advances Retina Research
Armed with a new ability to find retinal anomalies at the cellular level, neurobiologists at St. Jude Children's Research Hospital have made a discovery they hope will ultimately lead to a treatment for cancer of the retina. While much work remains, Oak Ridge National Laboratory's specialized tracing algorithm allows researchers to analyze thousands of cells instead of just a few dozen...
Gene Therapy in Ophthalmology Update 6: First-Ever Clinical Trial for the Autosomal Recessive Form of Retinitis Pigmentosa (arRP) is Underway
It has been difficult keeping up with the changing world of gene therapy in ophthalmology, but thanks to the Foundation Fighting Blindness, I learned yesterday about this new, and first clinical study for treating a rare form of retinitis pigmentosa, underway in Saudi Arabia.
Ophthalmology Compensation: How Does Your Salary Stack Up?
The ophthalmology-specific results of a physician compensation survey are summarized here for quick and easy consumption.
Medscape Ophthalmology
Medscape Ophthalmology
ThromboGenics submits ocriplasmin BLA with FDA to treat symptomatic VMA
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that it has submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin Intravitreal Injection, 2.5 mg/mL, for the treatment of symptomatic VMA including macular hole.
Male Gender and Obesity Up Risk for Postop Blindness (CME/CE)
(MedPage Today) -- Men and heavier patients who have spine surgery may be at a greater risk for postoperative blindness, researchers found.
DIY Home Electronic Contact Lens
We’ve been seeing intriguing research into electronic contact lenses over the last few years (see flashbacks below) that promises glucose and ocular pressure monitoring directly from the eye and augmented reality computer applications where data is displayed within the contact lens that only the user can see. Ben Krasnow, a tinkerer of elect (Read more...)
FDA clears OptiMedica’s Catalys Precision Laser System
Global ophthalmic company OptiMedica Corp. has announced the U.S. Food and Drug Administration (FDA) 510(k) market clearance of its Catalys Precision Laser System, a next generation laser cataract surgery system that brings unequaled precision and accuracy and a markedly streamlined workflow to the laser cataract procedure.
Azithromycin shows promise against trachoma-related blindness
A UCSF study shows a popular treatment for a potentially blinding eye infection is just as effective if given every six months versus annually. This randomized study on trachoma, the leading cause of infection-caused blindness in the world, could potentially treat twice the number of patients using the same amount of medication.
New pharma title from iSmithers ‘Update on Polymers for Ocular Drug Delivery’
The eye is the most easily accessible site for topical administration of a medication. Drugs are commonly applied to the eye for localised action on the surface or in the interior of the eye. A major problem in ocular therapeutics is the attainment of an optimal drug concentration at the site of action.
FDA Program Targets Rare Cataract Surgery Complication
Several agencies are now working together to track cases of toxic anterior segment syndrome and improve device safety.
Medscape Medical News
Medscape Medical News
FDA to Study Complication of Cataract Surgery
WASHINGTON (MedPage Today) -- A rare but potentially serious complication of cataract surgery has caught the attention of the FDA, which has launched a monitoring program to prevent outbreaks of toxic anterior segment syndrome (TASS).
Subscribe
